Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools, Benjamin L. Ebert, Gerlinde Wernig, Brian J P Huntly, Titus J. Boggon, Iwona Wlodarska, Jennifer J. Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey C. Lee, Stacey Gabriel, Thomas Mercher, Alan D'Andrea, Stefan Fröhling, Konstanze Döhner, Peter Marynen, Peter Vandenberghe & 9 others Ruben A. Mesa, Ayalew Tefferi, James D. Griffin, Michael J. Eck, William R. Sellers, Matthew Meyerson, Todd R. Golub, Stephanie J. Lee, D. Gary Gilliland

Research output: Contribution to journalArticle

2077 Citations (Scopus)

Abstract

Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase.

Original languageEnglish (US)
Pages (from-to)387-397
Number of pages11
JournalCancer Cell
Volume7
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Protein-Tyrosine Kinases
Granulocytes
Mutation
DNA
Cytogenetic Analysis
Missense Mutation
Internet
Alleles

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., ... Gilliland, D. G. (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7(4), 387-397. https://doi.org/10.1016/j.ccr.2005.03.023

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. / Levine, Ross L.; Wadleigh, Martha; Cools, Jan; Ebert, Benjamin L.; Wernig, Gerlinde; Huntly, Brian J P; Boggon, Titus J.; Wlodarska, Iwona; Clark, Jennifer J.; Moore, Sandra; Adelsperger, Jennifer; Koo, Sumin; Lee, Jeffrey C.; Gabriel, Stacey; Mercher, Thomas; D'Andrea, Alan; Fröhling, Stefan; Döhner, Konstanze; Marynen, Peter; Vandenberghe, Peter; Mesa, Ruben A.; Tefferi, Ayalew; Griffin, James D.; Eck, Michael J.; Sellers, William R.; Meyerson, Matthew; Golub, Todd R.; Lee, Stephanie J.; Gilliland, D. Gary.

In: Cancer Cell, Vol. 7, No. 4, 04.2005, p. 387-397.

Research output: Contribution to journalArticle

Levine, RL, Wadleigh, M, Cools, J, Ebert, BL, Wernig, G, Huntly, BJP, Boggon, TJ, Wlodarska, I, Clark, JJ, Moore, S, Adelsperger, J, Koo, S, Lee, JC, Gabriel, S, Mercher, T, D'Andrea, A, Fröhling, S, Döhner, K, Marynen, P, Vandenberghe, P, Mesa, RA, Tefferi, A, Griffin, JD, Eck, MJ, Sellers, WR, Meyerson, M, Golub, TR, Lee, SJ & Gilliland, DG 2005, 'Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis', Cancer Cell, vol. 7, no. 4, pp. 387-397. https://doi.org/10.1016/j.ccr.2005.03.023
Levine, Ross L. ; Wadleigh, Martha ; Cools, Jan ; Ebert, Benjamin L. ; Wernig, Gerlinde ; Huntly, Brian J P ; Boggon, Titus J. ; Wlodarska, Iwona ; Clark, Jennifer J. ; Moore, Sandra ; Adelsperger, Jennifer ; Koo, Sumin ; Lee, Jeffrey C. ; Gabriel, Stacey ; Mercher, Thomas ; D'Andrea, Alan ; Fröhling, Stefan ; Döhner, Konstanze ; Marynen, Peter ; Vandenberghe, Peter ; Mesa, Ruben A. ; Tefferi, Ayalew ; Griffin, James D. ; Eck, Michael J. ; Sellers, William R. ; Meyerson, Matthew ; Golub, Todd R. ; Lee, Stephanie J. ; Gilliland, D. Gary. / Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. In: Cancer Cell. 2005 ; Vol. 7, No. 4. pp. 387-397.
@article{6bc17695006b461aa60f2519c42585c4,
title = "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis",
abstract = "Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase.",
author = "Levine, {Ross L.} and Martha Wadleigh and Jan Cools and Ebert, {Benjamin L.} and Gerlinde Wernig and Huntly, {Brian J P} and Boggon, {Titus J.} and Iwona Wlodarska and Clark, {Jennifer J.} and Sandra Moore and Jennifer Adelsperger and Sumin Koo and Lee, {Jeffrey C.} and Stacey Gabriel and Thomas Mercher and Alan D'Andrea and Stefan Fr{\"o}hling and Konstanze D{\"o}hner and Peter Marynen and Peter Vandenberghe and Mesa, {Ruben A.} and Ayalew Tefferi and Griffin, {James D.} and Eck, {Michael J.} and Sellers, {William R.} and Matthew Meyerson and Golub, {Todd R.} and Lee, {Stephanie J.} and Gilliland, {D. Gary}",
year = "2005",
month = "4",
doi = "10.1016/j.ccr.2005.03.023",
language = "English (US)",
volume = "7",
pages = "387--397",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

AU - Levine, Ross L.

AU - Wadleigh, Martha

AU - Cools, Jan

AU - Ebert, Benjamin L.

AU - Wernig, Gerlinde

AU - Huntly, Brian J P

AU - Boggon, Titus J.

AU - Wlodarska, Iwona

AU - Clark, Jennifer J.

AU - Moore, Sandra

AU - Adelsperger, Jennifer

AU - Koo, Sumin

AU - Lee, Jeffrey C.

AU - Gabriel, Stacey

AU - Mercher, Thomas

AU - D'Andrea, Alan

AU - Fröhling, Stefan

AU - Döhner, Konstanze

AU - Marynen, Peter

AU - Vandenberghe, Peter

AU - Mesa, Ruben A.

AU - Tefferi, Ayalew

AU - Griffin, James D.

AU - Eck, Michael J.

AU - Sellers, William R.

AU - Meyerson, Matthew

AU - Golub, Todd R.

AU - Lee, Stephanie J.

AU - Gilliland, D. Gary

PY - 2005/4

Y1 - 2005/4

N2 - Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase.

AB - Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase.

UR - http://www.scopus.com/inward/record.url?scp=20244369569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244369569&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2005.03.023

DO - 10.1016/j.ccr.2005.03.023

M3 - Article

VL - 7

SP - 387

EP - 397

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 4

ER -